{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:58:41Z","timestamp":1779177521987,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Health Commission Medical and Health Science and Technology Project","award":["2022KY585"],"award-info":[{"award-number":["2022KY585"]}]},{"name":"General scientific research project of Zhejiang Provincial Department of Education","award":["Y202352079"],"award-info":[{"award-number":["Y202352079"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84247-w","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T14:33:38Z","timestamp":1736951618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Miaomiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"84247_CR1","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Schoffski","year":"2016","unstructured":"Schoffski, P. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387, 1629\u20131637. https:\/\/doi.org\/10.1016\/S0140-6736(15)01283-0 (2016).","journal-title":"Lancet"},{"key":"84247_CR2","doi-asserted-by":"publisher","unstructured":"Amdahl, J. et al. Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United Kingdom. Sarcoma 2014(481071). https:\/\/doi.org\/10.1155\/2014\/481071 (2014).","DOI":"10.1155\/2014\/481071"},{"key":"84247_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.soc.2011.12.003","volume":"21","author":"NB Jones","year":"2012","unstructured":"Jones, N. B., Iwenofu, H., Scharschmidt, T. & Kraybill, W. Prognostic factors and staging for soft tissue sarcomas: an update. Surg. Oncol. Clin. N Am. 21, 187\u2013200. https:\/\/doi.org\/10.1016\/j.soc.2011.12.003 (2012).","journal-title":"Surg. Oncol. Clin. N Am."},{"key":"84247_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"M Van Glabbeke","year":"1999","unstructured":"Van Glabbeke, M. et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens\u2013a European Organization for Research and Treatment of Cancer Soft Tissue and bone Sarcoma Group Study. J. Clin. Oncol. 17, 150\u2013157. https:\/\/doi.org\/10.1200\/JCO.1999.17.1.150 (1999).","journal-title":"J. Clin. Oncol."},{"key":"84247_CR5","doi-asserted-by":"publisher","first-page":"e20294","DOI":"10.1371\/journal.pone.0020294","volume":"6","author":"F Ducimetiere","year":"2011","unstructured":"Ducimetiere, F. et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 6, e20294. https:\/\/doi.org\/10.1371\/journal.pone.0020294 (2011).","journal-title":"PLoS One"},{"key":"84247_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1200\/JCO.1995.13.7.1537","volume":"13","author":"A Santoro","year":"1995","unstructured":"Santoro, A. et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13, 1537\u20131545. https:\/\/doi.org\/10.1200\/JCO.1995.13.7.1537 (1995).","journal-title":"J. Clin. Oncol."},{"key":"84247_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/00000421-199806000-00025","volume":"21","author":"SR Patel","year":"1998","unstructured":"Patel, S. R. et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am. J. Clin. Oncol. 21, 317\u2013321. https:\/\/doi.org\/10.1097\/00000421-199806000-00025 (1998).","journal-title":"Am. J. Clin. Oncol."},{"key":"84247_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi, Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 105, 1334\u20131342. https:\/\/doi.org\/10.1111\/cas.12488 (2014).","journal-title":"Cancer Sci."},{"key":"84247_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida, T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br. J. Cancer 110, 1497\u20131505. https:\/\/doi.org\/10.1038\/bjc.2014.80 (2014).","journal-title":"Br. J. Cancer"},{"key":"84247_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2165\/11207520-000000000-00000","volume":"71","author":"CM Perry","year":"2011","unstructured":"Perry, C. M. Eribulin. Drugs 71, 1321\u20131331, https:\/\/doi.org\/10.2165\/11207520-000000000-00000 (2011).","journal-title":"Drugs"},{"key":"84247_CR11","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","volume":"35","author":"GD Demetri","year":"2017","unstructured":"Demetri, G. D. et al. Activity of Eribulin in patients with Advanced Liposarcoma demonstrated in a Subgroup Analysis from a Randomized Phase III Study of Eribulin Versus Dacarbazine. J. Clin. Oncol. 35, 3433\u20133439. https:\/\/doi.org\/10.1200\/JCO.2016.71.6605 (2017).","journal-title":"J. Clin. Oncol."},{"key":"84247_CR12","doi-asserted-by":"publisher","first-page":"e0281402","DOI":"10.1371\/journal.pone.0281402","volume":"18","author":"J Lin","year":"2023","unstructured":"Lin, J., Fang, Q. & Zheng, X. Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. PLoS One 18, e0281402. https:\/\/doi.org\/10.1371\/journal.pone.0281402 (2023).","journal-title":"PLoS One"},{"key":"84247_CR13","unstructured":"Liu, G. E., Wu, H. S., Wu, J. H., Yang, J. & Li, L. HC. China guidelines for pharmacoeconomic evaluations (Chinese-English version). (2020)."},{"key":"84247_CR14","unstructured":"National Bureau of Statistics of China: National Data.. http:\/\/data.stats.gov.cn\/index.htm. (2023)."},{"key":"84247_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0272989X15622643","volume":"36","author":"QA Le","year":"2016","unstructured":"Le, Q. A. Structural uncertainty of Markov models for advanced breast Cancer: a Simulation Study of Lapatinib. Med. Decis. Mak. 36, 629\u2013640. https:\/\/doi.org\/10.1177\/0272989X15622643 (2016).","journal-title":"Med. Decis. Mak."},{"key":"84247_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.oraloncology.2019.04.022","volume":"94","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 94, 80\u201385. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.04.022 (2019).","journal-title":"Oral Oncol."},{"key":"84247_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2217\/fon-2018-0692","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. Future Oncol. 15, 181\u2013191. https:\/\/doi.org\/10.2217\/fon-2018-0692 (2019).","journal-title":"Future Oncol."},{"key":"84247_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler, H. G., Kong, S. X., Gerth, W. C., Mavros, P. & Jonsson, B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7, 518\u2013528. https:\/\/doi.org\/10.1111\/j.1524-4733.2004.75003.x (2004).","journal-title":"Value Health"},{"issue":"3","key":"84247_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o","volume":"9","author":"CJ Murray","year":"2000","unstructured":"Murray, C. J., Acharya, E. D. & Baltussen, A. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 9(3), 235\u2013251. (2000).","journal-title":"Health Econ."},{"key":"84247_CR20","doi-asserted-by":"publisher","first-page":"e748","DOI":"10.3747\/co.21.1899","volume":"21","author":"TE Delea","year":"2014","unstructured":"Delea, T. E. et al. Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada. Curr. Oncol. 21, e748\u2013759. https:\/\/doi.org\/10.3747\/co.21.1899 (2014).","journal-title":"Curr. Oncol."},{"key":"84247_CR21","doi-asserted-by":"publisher","unstructured":"Zuluaga-Sanchez, S. et al. Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States. Sarcoma 6703963. https:\/\/doi.org\/10.1155\/2018\/6703963 (2018).","DOI":"10.1155\/2018\/6703963"},{"key":"84247_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/annonc\/mdq339","volume":"22","author":"EJO Soini","year":"2011","unstructured":"Soini, E. J. O., San Andres, G., Joensuu, T. & B. & Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann. Oncol. 22, 215\u2013223. https:\/\/doi.org\/10.1093\/annonc\/mdq339 (2011).","journal-title":"Ann. Oncol."},{"key":"84247_CR23","doi-asserted-by":"publisher","unstructured":"Ding, H. et al. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. Eur. J. Cancer Care (Engl) 26. https:\/\/doi.org\/10.1111\/ecc.12733 (2017).","DOI":"10.1111\/ecc.12733"},{"key":"84247_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri, G. D. et al. Efficacy and safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized Multicenter Clinical Trial. J. Clin. Oncol. 34, 786\u2013793. https:\/\/doi.org\/10.1200\/JCO.2015.62.4734 (2016).","journal-title":"J. Clin. Oncol."},{"key":"84247_CR25","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","volume":"29","author":"X Garcia-Del-Muro","year":"2011","unstructured":"Garcia-Del-Muro, X. et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J. Clin. Oncol. 29, 2528\u20132533. https:\/\/doi.org\/10.1200\/JCO.2010.33.6107 (2011).","journal-title":"J. Clin. Oncol."},{"key":"84247_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10637-007-9086-z","volume":"26","author":"PA Zucali","year":"2008","unstructured":"Zucali, P. A. et al. The old drug dacarbazine as a second\/third line chemotherapy in advanced soft tissue sarcomas. Invest. New. Drugs 26, 175\u2013181. https:\/\/doi.org\/10.1007\/s10637-007-9086-z (2008).","journal-title":"Invest. New. Drugs"},{"key":"84247_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/0366-6999.147822","volume":"128","author":"X Zhao","year":"2015","unstructured":"Zhao, X. et al. Prognostic factors predicting the postoperative survival period following treatment for primary retroperitoneal liposarcoma. Chin. Med. J. (Engl.) 128, 85\u201390. https:\/\/doi.org\/10.4103\/0366-6999.147822 (2015).","journal-title":"Chin. Med. J. (Engl)"},{"key":"84247_CR28","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/13696998.2019.1588125","volume":"22","author":"M Liao","year":"2019","unstructured":"Liao, M. et al. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China. J. Med. Econ. 22, 584\u2013592. https:\/\/doi.org\/10.1080\/13696998.2019.1588125 (2019).","journal-title":"J. Med. Econ."},{"key":"84247_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.36469\/9834","volume":"3","author":"G Tremblay","year":"2016","unstructured":"Tremblay, G., Majethia, U., Kontoudis, I. & De Rosendo, J. Cost effectiveness analysis of Eribulin Mesylate as a treatment for metastatic breast Cancer in Spain: management in the later line of Therapy. J. Health Econ. Outcomes Res. 3, 180\u2013193. https:\/\/doi.org\/10.36469\/9834 (2016).","journal-title":"J. Health Econ. Outcomes Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84247-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T14:33:46Z","timestamp":1736951626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84247-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84247"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84247-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2084"}}